Authors
Jonathan T Yang, N Ari Wijetunga, Elena Pentsova, Suzanne Wolden, Robert J Young, Denise Correa, Zhigang Zhang, Junting Zheng, Alexa Steckler, Weronika Bucwinska, Ashley Bernstein, Allison Betof Warner, Helena Yu, Mark G Kris, Andrew D Seidman, Jessica A Wilcox, Rachna Malani, Andrew Lin, Lisa M DeAngelis, Nancy Y Lee, Simon N Powell, Adrienne Boire
Publication date
2022/11/20
Journal
Journal of Clinical Oncology
Volume
40
Issue
33
Pages
3858-3867
Publisher
Wolters Kluwer Health
Description
PURPOSE
Photon involved-field radiotherapy (IFRT) is the standard-of-care radiotherapy for patients with leptomeningeal metastasis (LM) from solid tumors. We tested whether proton craniospinal irradiation (pCSI) encompassing the entire CNS would result in superior CNS progression-free survival (PFS) compared with IFRT.
PATIENTS AND METHODS
We conducted a randomized, phase II trial of pCSI versus IFRT in patients with non–small-cell lung cancer and breast cancers with LM. We enrolled patients with other solid tumors to an exploratory pCSI group. For the randomized groups, patients were assigned (2:1), stratified by histology and systemic disease status, to pCSI or IFRT. The primary end point was CNS PFS. Secondary end points included overall survival (OS) and treatment-related adverse events (TAEs).
RESULTS
Between April 16, 2020, and October 11, 2021, 42 and 21 patients were randomly …
Total citations
Scholar articles
JT Yang, NA Wijetunga, E Pentsova, S Wolden… - Journal of Clinical Oncology, 2022